Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
You may also be interested in...
Becerra Takes The Helm At HHS; More Visibility On Administration’s Drug Pricing Priorities To Follow
Becerra’s HHS has a new crop of former Capitol Hill staffers in its policy ranks who are well versed on legislation in the health care realm, including prescription drug pricing reform. That will help advance the Administration’s agenda.
Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.
Chiquita Brooks-LaSure would be in a key position to implement the Biden Administration’s drug pricing priorities and is familiar with the balancing act needed when considering competing interests among stakeholders as policies are shaped.